FrancophonIA/ELRC3.0 huggingface dataset:
English: Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface.
Estonian: Klopidogreel peatab trombotsüütide agregatsiooni, blokeerides adenosiindifosfaadi seondumise teatud retseptoriga trombotsüütide pinnal.
English: When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together).
Estonian: Veri hüübib teatud vererakkudetrombotsüütide (vereliistakute) - agregatsiooni (kokkukleepumise) tõttu.
English: • recently had an ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
Estonian: • Hiljutine isheemiline insult (peaaju teatud osa verevarustushäiretest tingitud insult).
English: Clopidogrel TAD is a medicine used to prevent problems caused by blood clots in adults who have:
Estonian: Ravim Clopidogrel TAD on antikoagulant (hüübimisvastane ravim) ja seda kasutatakse täiskasvanutel trombidest (soonesisestest verehüüvetest) põhjustatud probleemide ennetamiseks järgmiste seisundite korral.
English: How has Clopidogrel TAD been studied?
Estonian: Kuidas ravimit Clopidogrel TAD uuriti?
English: How does Clopidogrel TAD work?
Estonian: Kuidas Clopidogrel TAD toimib?
English: • a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots).
Estonian: • Äge koronaarsündroom, mille korral tuleb ravimit Clopidogrel TAD võtta koos aspiriiniga (samuti antikoagulant).
English: The active substance in Clopidogrel TAD, clopidogrel, is an inhibitor of platelet aggregation.
Estonian: Ravimi Clopidogrel TAD toimeaine klopidogreel on trombotsüütide agregatsiooni inhibiitor, mis aitab ennetada trombide (soonesiseste verehüüvete) tekkimist.
English: How is Clopidogrel TAD used?
Estonian: Kuidas ravimit Clopidogrel TAD kasutatakse?
English: What are the benefits and risks of Clopidogrel TAD?
Estonian: Milles seisneb ravimi Clopidogrel TAD kasulikkus ja mis riskid ravimiga kaasnevad?
English: Clopidogrel TAD can only be obtained with a prescription.
Estonian: Clopidogrel TAD on retseptiravim.
English: This summary was last updated in 11-2017.
Estonian: Kokkuvõtte viimane uuendus: 11-2017.
English: This replaces the missing protein, thereby relieving the symptoms of the disease.
Estonian: See asendab puuduva valgu, leevendades seeläbi haiguse sümptomeid.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Spinraza on 30 May 2017.
Estonian: Euroopa Komisjon andis Spinraza müügiloa, mis kehtib kogu Euroopa Liidus, 30. mail 2017.
English: What measures are being taken to ensure the safe and effective use of Spinraza?
Estonian: Mis meetmed võetakse, et tagada Spinraza ohutu ja efektiivne kasutamine?
English: In babies some side effects could not be assessed, as they could not communicate them.
Estonian: Vastsündinutel ei saanud hinnata teatud kõrvalnähtusid, sest nad ei ole võimelised neist teatama.
English: In its assessment, the European Medicines Agency recognised the serious nature of the disease and the urgent need for effective treatments.
Estonian: Oma hinnangus mõistis Euroopa Ravimiamet haiguse rasket olemust ja edasilükkamatut vajadust efektiivsete ravimeetodite järele.
English: The disease is linked to a defect on chromosome 5q and symptoms usually start shortly after birth.
Estonian: Haigus on seotud defektiga 5. kromosoomi pikas õlas (5q) ja tavaliselt hakkavad sümptomid tekkima üsna pea pärast sündimist.
English: Although the medicine was not tested in patients with the most severe and the mildest forms of SMA, it is expected to provide similar benefits to these patients.
Estonian: Kuigi ravimit ei ole uuritud spinaalse lihasatroofia kõige raskemate ja kergemate vormidega patsientidel, eeldatakse siiski sarnaste kasulike toimete saavutamist ka nendel patsientidel.
English: Spinraza nusinersen
Estonian: Spinraza nusinerseen
English: The Agency therefore decided that Spinraza's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Spinraza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: What is Spinraza and what is it used for?
Estonian: Mis on Spinraza ja milleks seda kasutatakse?
English: The most common side effects with Spinraza (which may affect more than 1 in 10 people) are headache, back pain and vomiting.
Estonian: Spinraza kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on peavalu, seljavalu ja oksendamine.
English: The SMN protein is made from two genes, SMN1 and SMN2.
Estonian: SMN-valku toodetakse kahe geeni põhjal - SMN1 ja SMN2.
English: The medicine is available as a solution for injection in 12 mg vials.
Estonian: Ravimit turustatakse süstelahusena 12 mg viaalides.
English: After one year of treatment, 51% of babies receiving Spinraza (37 out of 73) showed progress in developing head control, rolling, sitting, crawling, standing and walking, whereas no similar progress was seen in any of the babies who received placebo.
Estonian: Üheaastase ravi järel täheldati 51% Spinrazat saanud lastest (37 last 73st) pea hoidmise, pööramise, istumise, roomamise, seismise ja kõndimise arengut, samas kui sarnast arengut ei täheldatud ühelgi platseebot saanud lapsel.
English: Other information about Spinraza
Estonian: Muu teave Spinraza kohta
English: Why is Spinraza approved?
Estonian: Miks Spinraza heaks kiideti?
English: The first dose should be followed by 3 more doses after 2, 4, and 9 weeks and then one dose every 4 months thereafter.
Estonian: annust vastavalt 2, 4 ja 9 nädalat hiljem ning seejärel tuleb jätkata ravimi manustamist ühe annuse kaupa iga 4 kuu järel.
English: The recommended dose is 12 mg (one vial), given as soon as possible after the patient has been diagnosed with SMA.
Estonian: Soovitatav annus on 12 mg (üks viaal), mis tuleb manustada võimalikult kiiresti pärast spinaalse lihasatroofia diagnoosimist patsiendil.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Spinraza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Spinraza kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: These side effects are thought to be caused by the injections into the spine used to give the medicine.
Estonian: Need kõrvalnähud arvatakse olevat tingitud ravimi manustamiseks kasutatavatest seljasüstidest.
English: It is not intended to provide practical advice on how to use Spinraza.
Estonian: Hindamisaruandes ei anta Spinraza kasutamise praktilisi nõuandeid.
English: Spinraza has been shown to lead to clinically meaningful improvements in young children with varying degrees of disease severity.
Estonian: Spinrazaga on tõendatud kliiniliselt tähenduslik paranemine haiguse erinevate raskusastmetega väikelastel.
English: The full EPAR for Spinraza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Spinraza kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Spinraza contains the active substance nusinersen.
Estonian: Spinraza sisaldab toimeainena nusinerseeni.
English: This is a summary of the European public assessment report (EPAR) for Spinraza.
Estonian: See on ravimi Spinraza Euroopa avaliku hindamisaruande kokkuvõte.
English: What are the risks associated with Spinraza?
Estonian: Mis riskid Spinrazaga kaasnevad?
English: Side effects were considered manageable, with most side effects related to the way the medicine is given.
Estonian: Kõrvalnähte peeti ohjatavateks, kusjuures enamik kõrvalnähte on seotud ravimi manustamisviisiga.
English: The company that markets Spinraza will complete ongoing studies of the long-term safety and effectiveness of the medicine in patients who are showing symptoms of SMA and patients not yet showing symptoms.
Estonian: Spinrazat turustav ettevõte viib lõpuni ravimi pikaajalise ohutuse ja efektiivsuse uuringud spinaalse lihasatroofia sümptomitega ja veel sümptomiteta patsientidel.
English: One main study, involving 121 babies (of an average age of 7 months) with SMA, showed that Spinraza is effective in improving movement when compared with placebo (sham injection).
Estonian: Ühes põhiuuringus, kus osales 121 spinaalse lihasatroofiaga vastsündinut (kelle keskmine vanus oli 7 kuud), tõendati Spinraza efektiivsust liikumisvõime parandamisel võrreldes platseeboga (toimeaineta süstiga).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Spinraza have also been included in the summary of product characteristics and the package leaflet.
Estonian: Spinraza ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: In addition, most babies treated with Spinraza survived for longer and needed breathing support later than those given placebo.
Estonian: Peale selle elas enamik Spinrazaga ravitud vastsündinuid kauem ja vajadus hingamisaparaadi järele tekkis neil hiljem kui platseebot saanud vastsündinutel.
English: Spinraza is a synthetic anti-sense oligonucleotide (a type of genetic material) that enables the SMN2 gene to produce full length protein, which is able to work normally.
Estonian: Spinraza on sünteetiline antisenss oligonukleotiid (geneetilise materjali tüüp), mis võimaldab SMN2 geenil toota täispikkuses valku, mis toimiks normaalselt.
English: After 15 months of treatment, 57% of children receiving Spinraza showed improvement in movement compared with 26% of children on placebo.
Estonian: Pärast 15-kuulist ravi paranes liikumisvõime 57%-l Spinrazat saanud lastest ja 26%-l platseebot saanud lastest.
English: Because the number of patients with SMA is low, the disease is considered ‘rare', and Spinraza was designated an ‘orphan medicine' (a medicine used in rare diseases) on 2 April 2012.
Estonian: Et spinaalse lihasatroofiaga patsientide arv on väike ja see haigus esineb harva, nimetati Spinraza 2. aprillil 2012 harvikravimiks.
English: Spinraza can only be obtained with a prescription and treatment should be started by a doctor with experience in the treatment of SMA.
Estonian: Spinraza on retseptiravim ja ravi peab alustama spinaalse lihasatroofia ravis kogenud arst.
English: For the full list of all side effects and restrictions with Spinraza, see the package leaflet.
Estonian: Spinraza kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: For practical information about using Spinraza, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Spinraza kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Spinraza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Spinrazaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Treatment should be continued for as long as the patient benefits from it. For further information, see the package leaflet.
Estonian: Ravi tuleb jätkata, kuni sellest on patsiendile kasu.
English: Another study assessed Spinraza's effectiveness in children whose SMA was less severe and diagnosed at a later stage (average age of 3 years).
Estonian: Praegu on käimas veel üks uuring, milles uuritakse Spinraza efektiivsust lastel, kellel on kergem spinaalse lihasatroofia vorm ja kelle haigus on diagnoositud hiljem (keskmine vanus 3 aastat).
English: Patients with SMA lack a protein called ‘survival motor neuron' (SMN) protein, which is essential for motor neurons (nerve cells from the spinal cord that control muscle movements) to survive and function normally.
Estonian: Spinaalse lihasatroofiaga patsientidel puudub valk nimega „motoneuroni ellujäämise valk“ (SMN, survival (of) motor neuron), mis on motoneuronite (närvirakud seljaajus, mis reguleerivad lihaste liikumist) ellujäämiseks ja normaalseks funktsioneerimiseks hädavajalik.
English: How does Spinraza work?
Estonian: Kuidas Spinraza toimib?
English: Patients with SMA lack the SMN1 gene but have the SMN2 gene, which mostly produces a short SMN protein that does not work as well as a full-length protein.
Estonian: Spinaalse lihasatroofiaga patsientidel puudub SMN1 geen, kuid neil on SMN2 geen, mille põhjal toodetakse valdavalt lühikest SMN-valku, mis ei toimi nii hästi kui täispikkuses valk.
English: It is given by intrathecal injection (into the lower back, directly into the spine) by a doctor or nurse experienced in carrying out this procedure.
Estonian: Ravimit manustab selle protseduuri tegemises kogenud arst või õde intratekaalse süstena (alaselga, otse lülisambakanalisse).
English: What benefits of Spinraza have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Spinraza kasulikkus?
English: How is Spinraza used?
Estonian: Kuidas Spinrazat kasutatakse?
English: Spinraza is a medicine used to treat 5q spinal muscular atrophy (SMA), a genetic disease that causes weakness and wasting of the muscles including the lung muscles.
Estonian: Spinaalne lihasatroofia on geneetiline haigus, mis põhjustab lihaste, sealhulgas hingamislihaste, nõrkust ja kõhetumist.
English: MA (EU) number (Invented) name
Estonian: Väljamõeldud nimetus
English: Other medicines and Hyrimoz
Estonian: Muud ravimid ja Hyrimoz
English: Contents of the pack and other information What Hyrimoz contains
Estonian: Pakendi sisu ja muu teave Mida Hyrimoz sisaldab
English: * further information is found elsewhere in sections 4.3, 4.4 and 4.8 ** including open label extension studies including spontaneous reporting data
Estonian: Halvenenud kuulmine * lisainformatsioon on toodud mujal lõikudes 4.3, 4.4 ja 4.8 ** sealhulgas avatud jätku-uuringud sealhulgas spontaansed teated
English: Keep this Patient Reminder Card with you during your treatment and for 4 months after your (or your child's) last injection of Hyrimoz.
Estonian: Kandke patsiendi teabekaarti endaga kaasas ravi ajal ja 4 kuud pärast oma (või oma lapse) viimast Hyrimoz'i süstet.
English: Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4).
Estonian: Aktiivne tuberkuloos või teised rasked infektsioonid, nt sepsis ja oportunistlikud infektsioonid (vt lõik 4.4).
English: Keep Hyrimoz and all medicines out of the reach of children.
Estonian: Hoidke Hyrimoz ja kõik ravimid laste eest kättesaamatus kohas.
English: If you have any questions, please talk to a doctor, pharmacist or nurse who is familiar with Hyrimoz.
Estonian: Kui teil on küsimusi, pidage nõu arsti, apteekri või meditsiiniõega, kes on Hyrimoz'iga tuttavad.
English: If you accidentally inject Hyrimoz more frequently than you should, call your doctor or pharmacist and explain that you have taken more than required.
Estonian: Kui te süstite Hyrimoz'i kogemata sagedamini kui ette nähtud, helistage oma arstile või apteekrile ning öelge talle, et süstisite rohkem kui vaja.
English: The potential risk with the combination of azathioprine or 6mercaptopurine and Hyrimoz should be carefully considered.
Estonian: Asatiopriini või 6-merkaptopuriini ja Hyrimoz'i samaaegsel kasutamisel esinevat võimalikku riski tuleb hoolikalt kaaluda.
English: The impact of long-term treatment with adalimumab on the development of autoimmune diseases is unknown.
Estonian: Adalimumabiga pikaajalise ravi mõju autoimmuunhaiguste tekkele ei ole teada.
English: • Certain vaccines contain living but weakened forms of disease-causing bacteria or viruses and should not be given during treatment with Hyrimoz in case they cause infections.
Estonian: • Teatud vaktsiinid sisaldavad elus, kuid nõrgestatud haigust põhjustavaid baktereid või viiruseid ja neid ei tohi Hyrimoz'i kasutamise ajal manustada, sest nad võivad põhjustada infektsioone.
English: Hyrimoz can reduce the number of nodules and abscesses you have, and the pain that is often associated with the disease.
Estonian: Hyrimoz'i toimel võib väheneda teil esinevate kühmude ja abstsesside arv ning valu, mis sageli haigusega kaasneb.
English: Side effects may occur up to 4 months or more after the last Hyrimoz injection.
Estonian: Kõrvaltoimed võivad avalduda vähemalt kuni 4 kuu jooksul pärast viimast Hyrimoz'i süsti.
English: Hyrimoz can also be given alone.
Estonian: Hyrimoz'i võib kasutada ka üksinda.
English: • If you have allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling or rash, do not inject more Hyrimoz and contact your doctor immediately, since in rare cases, these reactions can be life-threatening.
Estonian: • Kui teil tekib allergiline reaktsioon koos sümptomitega, nagu rindkere pingsus, vilisev hingamine, pearinglus, tursed või lööve, ärge rohkem Hyrimoz'i süstige ja võtke otsekohe ühendust oma arstiga, sest harvadel juhtudel võivad need reaktsioonid olla eluohtlikud.
English: - Your doctor will also give you a Patient Reminder Card, which contains important safety information that you need to be aware of before you are given Hyrimoz and during treatment with Hyrimoz.
Estonian: - Arst annab teile patsiendi teabekaardi, mis sisaldab tähtsat ohutusalast informatsiooni, millest peate teadlik olema enne Hyrimoz'iga ravi alustamist ja ravi ajal.
English: • If you are about to have surgery or dental procedures tell your doctor that you are taking Hyrimoz.
Estonian: • Kui teil planeeritakse kirurgilisi või hambaraviprotseduure, informeerige oma arsti, et te kasutate Hyrimoz'i.
English: What you need to know before you use Hyrimoz Do not use Hyrimoz
Estonian: Mida on vaja teada enne Hyrimoz'i kasutamist Ärge kasutage Hyrimoz'i
English: • Hyrimoz should only be used during a pregnancy if needed.
Estonian: • Hyrimoz'i tohib raseduse ajal kasutada üksnes vajaduse korral.
English: Before initiation of therapy with Hyrimoz, all patients must be evaluated for both active and inactive (“latent”) tuberculosis infection.
Estonian: Enne Hyrimoz'iga ravi alustamist tuleb kõiki patsiente uurida nii aktiivse kui inaktiivse (latentse) tuberkuloosi suhtes.
English: • If you are over 65 years you may be more susceptible to infections while taking Hyrimoz.
Estonian: • Kui olete vanem kui 65-aastane, võib teil Hyrimoz'i võtmise ajal olla suurem kalduvus infektsioonide tekkeks.
English: Concomitant corticosteroids may be tapered in accordance with clinical practice starting two weeks after initiating treatment with Hyrimoz.
Estonian: Samaaegselt kasutatavate kortikosteroidide annust võib järk-järgult vähendada vastavalt kliinilisele praktikale, alustades kaks nädalat pärast Hyrimoz'iga ravi alustamist.
English: • inject Hyrimoz 15-30 minutes after taking it out of the refrigerator for a more comfortable injection.
Estonian: • süstite Hyrimoz'i 15…30 minutit pärast külmkapist väljavõtmist, et süste oleks mugavam.
English: If an anaphylactic reaction or other serious allergic reaction occurs, administration of Hyrimoz should be discontinued immediately and appropriate therapy initiated.
Estonian: Anafülaktilise reaktsiooni või muu raske allergilise reaktsiooni tekkimisel tuleb Hyrimoz'i manustamine otsekohe lõpetada ja alustada sobivat ravi.
English: What Hyrimoz is and what it is used for
Estonian: Mis ravim on Hyrimoz ja milleks seda kasutatakse
English: If you have mild heart failure and you are being treated with Hyrimoz, your heart failure status must be closely monitored by your doctor.
Estonian: Kui teil on kerge südamepuudulikkus ja te saate ravi Hyrimoz'iga, peab arst hoolikalt jälgima teie südamepuudulikkuse seisundit.
English: Tell your doctor if you are taking azathioprine or mercaptopurine with Hyrimoz.
Estonian: Rääkige oma arstile kui te võtate asatiopriini või 6-merkaptopuriini koos Hyrimoz'iga.
English: Taking these results into consideration, Hyrimoz is recommended for use in combination with MTX and for use as monotherapy in patients for whom MTX use is not appropriate (see section 4.2).
Estonian: Neid tulemusi arvestades soovitatakse Hyrimoz'i kasutada kombinatsioonis MTX-ga või monoteraapiana patsientidel, kellel MTX-i kasutamine ei ole kohane (vt lõik 4.2)
English: By attaching to TNFα, Hyrimoz blocks its action and reduces the inflammation in these diseases.
Estonian: Seondudes TNFα-ga blokeerib Hyrimoz selle ja vähendab nende haigustega kaasnevat põletikulist protsessi.
English: If you forget to give yourself an injection, you should inject the next dose of Hyrimoz as soon as you remember.
Estonian: Kui te unustate end süstida, manustage Hyrimoz'i järgmine annus niipea kui meelde tuleb.
English: What Hyrimoz looks like and contents of the pack
Estonian: Kuidas Hyrimoz välja näeb ja pakendi sisu
English: • If you have an infection, including long-term or localised infection (for example leg ulcer), consult your doctor before starting Hyrimoz.
Estonian: • Kui teil esineb infektsioon (sh pikaajaline või piirdunud infektsioon, näiteks jala haavand), konsulteerige enne Hyrimoz'i kasutamist oma arstiga.
English: Figure A: Hyrimoz SensoReady pen parts
Estonian: Joonis A: Hyrimoz'i SensoReady pensüstli osad
English: You should continue to inject Hyrimoz for as long as your doctor has told you.
Estonian: Hyrimoz'i süstimist tuleb jätkata senikaua, kui arst on teile öelnud.
English: Alternatively, if a patient has stopped Hyrimoz and signs and symptoms of disease recur, Hyrimoz may be re-administered.
Estonian: Kui patsient on lõpetanud Hyrimoz'i kasutamise ning haiguse nähud ja sümptomid taastuvad, võib Hyrimoz'i uuesti manustada.
English: Detailed instructions on how to inject Hyrimoz are provided in section 7, “Instructions for use”.
Estonian: Täpsed juhised, kuidas Hyrimoz'i süstida, on toodud lõigus 7 „Kasutusjuhend“.
English: Patients treated with Hyrimoz should be given the Patient Reminder Card.
Estonian: Hyrimoz'iga ravi saavatele patsientidele tuleb anda patsiendi teabekaart.
English: Hyrimoz therapy should not be continued in patients failing to respond within this time period.
Estonian: Hyrimoz'iga ravi ei tohi jätkata patsientidel, kes ei saavuta selle perioodi jooksul ravivastust.
English: It is important that you tell your baby's doctors and other health care professionals about your Hyrimoz use during your pregnancy so they can decide when your baby should receive any vaccine.
Estonian: On tähtis, et te räägiksite oma lapse arstile ja teistele arstidele teie raseduse aegsest Hyrimoz'iga ravist, et nad saaksid otsustada, millal teie last vaktsineerida.
English: • It is important that you tell your baby's doctors and other health care professionals about your Hyrimoz use during your pregnancy before the baby receives any vaccine (for more information on vaccines see the “Warnings and precautions” section).
Estonian: • On tähtis, et te räägiksite enne teie lapse vaktsineerimist oma lapse arstile ja teistele arstidele teie raseduse aegsest Hyrimoz'iga ravist (lisateavet vaktsiinide kohta vaadake vaktsineerimist puudutavast lõigust „Hoiatused ja ettevaatusabinõud“).
English: Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Hyrimoz in patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.
Estonian: Tuberkuloosivastase profülaktilise ravi läbiviimist enne ravi alustamist Hyrimoz'iga tuleb samuti kaaluda patsientidel, kellel on mitmeid või olulisi tuberkuloosi riskitegureid vaatamata negatiivsele tuberkuloositestile ja patsientidel kellel on anamneesis latentne või aktiivne tuberkuloos ja kelle puhul ravikuuri läbimine pole kinnitust leidnud.